Molina Healthcare (NYSE:MOH) Price Target Lowered to $180.00 at Mizuho

Molina Healthcare (NYSE:MOH) had its target price lowered by Mizuho from $220.00 to $180.00 in a report released on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

MOH has been the topic of several other reports. Wells Fargo & Company set a $141.00 price objective on Molina Healthcare and gave the company an “equal weight” rating in a research report on Friday, February 20th. Barclays decreased their price target on shares of Molina Healthcare from $164.00 to $133.00 and set an “underweight” rating on the stock in a report on Tuesday, February 10th. Truist Financial decreased their target price on Molina Healthcare from $190.00 to $145.00 and set a “hold” rating for the company in a report on Tuesday, February 17th. The Goldman Sachs Group decreased their price target on shares of Molina Healthcare from $167.00 to $124.00 and set a “neutral” rating for the company in a research report on Wednesday, February 11th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $224.00 price objective on shares of Molina Healthcare in a research report on Tuesday, January 6th. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $153.29.

Molina Healthcare Price Performance

MOH stock opened at $149.27 on Thursday. The firm has a 50 day moving average of $164.22 and a 200-day moving average of $167.35. The company has a market cap of $7.69 billion, a price-to-earnings ratio of 17.44 and a beta of 0.52. Molina Healthcare has a 12-month low of $121.06 and a 12-month high of $359.97. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.97.

Molina Healthcare (NYSE:MOH) last posted its earnings results on Thursday, February 5th. The company reported ($2.75) EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($3.18). Molina Healthcare had a return on equity of 13.60% and a net margin of 1.04%.The firm had revenue of $11.38 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the previous year, the firm posted $5.05 earnings per share. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. Molina Healthcare has set its FY 2026 guidance at 5.000- EPS. As a group, equities analysts expect that Molina Healthcare will post 24.4 EPS for the current fiscal year.

Institutional Trading of Molina Healthcare

Several hedge funds have recently made changes to their positions in the stock. Torren Management LLC bought a new stake in Molina Healthcare in the 4th quarter valued at about $26,000. Miller Global Investments LLC acquired a new stake in Molina Healthcare in the fourth quarter worth approximately $27,000. Cromwell Holdings LLC lifted its holdings in shares of Molina Healthcare by 211.9% in the fourth quarter. Cromwell Holdings LLC now owns 184 shares of the company’s stock valued at $32,000 after buying an additional 125 shares during the period. Quarry LP bought a new position in shares of Molina Healthcare during the 4th quarter valued at about $32,000. Finally, Triumph Capital Management boosted its holdings in Molina Healthcare by 4,625.0% during the fourth quarter. Triumph Capital Management now owns 189 shares of the company’s stock worth $33,000 after buying an additional 185 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

About Molina Healthcare

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.